The startup develops an at-home medical device for complete blood count (CBC) analysis, including five-part white blood cell differentials and kidney and liver function panels. This technology enables clinicians to gather essential blood data for decentralized clinical trials and monitor chemotherapy side effects, facilitating telemedical consultations.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional complete blood count (CBC) analysis requires sending samples to a centralized lab, resulting in turnaround times that can delay treatment decisions and increase costs. This process can be particularly burdensome for patients in remote areas or those participating in decentralized clinical trials, where frequent blood monitoring is essential.
Solution
This startup is developing a point-of-care device that performs complete blood count (CBC) analysis, including five-part white blood cell differentials, as well as kidney and liver function panels, directly in the home or clinic. The device aims to provide rapid results, enabling clinicians to make timely decisions and monitor patient health more effectively. By decentralizing blood testing, the technology facilitates remote patient monitoring, supports decentralized clinical trials, and enhances the efficiency of telemedicine consultations.
Target Audience
The primary target audience includes clinicians, researchers conducting decentralized clinical trials, and patients requiring frequent blood monitoring, particularly those in remote locations or participating in telemedicine programs.
Features
- Point-of-care CBC analysis with five-part white blood cell differentials
- Kidney and liver function panel testing
- Compact, user-friendly design for in-home or clinical use
- Rapid results for timely clinical decision-making
- Data connectivity for seamless integration with electronic health records (EHRs)